BPC-157 in Costa Rica: what the research says and what is still unknown
· Novatheris
Anyone searching for BPC-157 in Costa Rica tends to find the same thing: big promises and thin sources. This article does the opposite. It gathers what has actually been published on BPC-157 and on TB-500, the two peptides that come together in our research vial, and marks clearly where the evidence ends.
They are two different molecules with two different histories. It helps to look at each one alone before looking at them together.
What BPC-157 is
BPC-157 is a chain of 15 amino acids. Its sequence is GEPPPGKPADDAGLV, its formula C62 H98 N16 O22, and it weighs about 1419.5 Da. It is derived from a sequence found in human gastric juice, which is why it is sometimes called a gastric pentadecapeptide.
In rodents it has been studied mostly in tendon, muscle and gut. The most cited paper is from 2003: in rats with a transected Achilles tendon, the treated group showed faster tendon closure, and in culture the peptide stimulated the growth of tendocytes, the cells of the tendon (Staresinic et al., 2003). The authors attribute that effect to new vessel formation and the nitric oxide pathway.
That is a finding in rats. It says nothing yet about people.
What is known about how it moves through the body
There is only one published pharmacokinetic study, meaning a study of how long it lasts and how it spreads through the body, and it is in animals. In rats and beagle dogs, the half-life was under 30 minutes, with linear kinetics (He et al., 2022).
The same group published a 28-day preclinical safety study in rats and dogs. Its abstract describes it as well tolerated with no serious toxicity (Xu et al., 2020).
In humans there is not a single published pharmacokinetic study. None.
Almost everything is animal research
This is the part that usually gets left out. A 2025 systematic review screened 544 articles and kept 36: 35 preclinical and 1 clinical. The authors write that they found no clinical safety data (Vasireddi et al., 2025).
Another detail carries weight. Of the 226 PubMed records on BPC-157, 175 list the same Croatian researcher as an author, from the group that first described it. Three-quarters of the literature comes from a single team, and no independent group has replicated the findings in people.
In humans there are three pilot studies, all without a control group, with fewer than 30 people in total, all first-authored by the same person:
- A knee case series (Lee and Padgett, 2021).
- An interstitial cystitis pilot (Lee, Walker and Ayadi, 2024).
- A two-person safety pilot (Lee and Burgess, 2025).
Without a control group you cannot separate the effect of the peptide from the passage of time or from expectation. That is why these pilots are useful for raising questions, not for answering them.
A 2026 review sums it up plainly: no validated formulation, no validated regimen and no completed phase II trial (Mateescu et al., 2026). A 2025 narrative review asks the question right in its title, regeneration or risk (McGuire et al., 2025).
What TB-500 is, and why it is not thymosin β4
TB-500 is a seven-amino-acid peptide with an acetylated end: Ac-LKKTETQ, formula C38 H68 N10 O14, about 889 Da. It matches residues 17 to 23 of thymosin β4, the region that binds actin.
Its chemical identity was established in 2012, when an analytical laboratory synthesized and characterized the fragment found in the product already in circulation (Esposito et al., 2012).
There is a very common mix-up here. Full thymosin β4 has 43 amino acids and weighs about 4963 Da. TB-500 is just a seven-residue piece of it. The human studies sometimes cited in support of TB-500 were run with the full protein: an intravenous trial in healthy volunteers (Ruff et al., 2010) and an eye-drop trial in dry eye (Sosne, Dunn and Kim, 2015). Those are a different molecule, with a different weight and different behavior.
For the TB-500 fragment there is not one published human study, by any route. There is also no half-life or bioavailability data, in humans or animals. Two 2026 sports medicine reviews reach the same point: indications, amounts, frequency and duration are unknown (Mendias and Awan, 2026; Mayfield et al., 2026).
The only study that put them together
If the vial holds both, the logical question is what happens when they are combined. Exactly one study has measured it.
In 32 rats with a repaired Achilles tendon, groups given BPC-157, TB-500 or both were compared. The TB-500 arm reached statistical significance in maximum load to failure, that is, how much force the tendon held before breaking. The BPC-157 arm did not. And combining the two gave no additional benefit over using either one alone (Biçer et al., 2026).
It is one study, in rats, at 4 weeks. It counts as a data point and nothing more. Adding two peptides does not add up their results, and this paper shows that on a small scale.
What is still unknown
To keep it clear, in a list:
- There is no human pharmacokinetic data for either one.
- There are no controlled human trials of BPC-157, and no human studies of any kind with TB-500.
- There is no data on repeated exposure over months.
- The BPC-157 literature depends almost entirely on one group.
- The combination has been tested once, in rats.
That is the real state of the field. Any text that talks about results in people with more certainty than this is saying more than what has been published.
How the vial is stored
Both peptides come lyophilized, which means dry: a powder whose water was removed with cold and vacuum. In that form they are more stable.
The powder is kept at -20 °C, closed and away from bright light. Before opening, the vial should reach room temperature while still sealed, so moisture does not condense inside. Once reconstituted, it goes to 2 to 8 °C and for a short time. The best practice is to split the solution into small portions, so the same vial is not frozen and thawed again and again.
Purity and delivery in Costa Rica
Every batch of the BPC-157 / TB-500 vial is sent to an outside laboratory. The report published today is from Freedom Diagnostics, for the 10 mg vial, and you can see it in full exactly as the laboratory issues it. The standard we ask for is +99.5% purity.
Delivery takes 2 hours inside the GAM, the Greater Metropolitan Area around San José, and 24 hours in the rest of the country.
If you are putting together a research protocol, the BPC-157 / TB-500 page has the compound data and its storage note, and the BPC-157 / TB-500 lab analysis has the batch report. For research use only.